Precigen shares are trading higher after the company study data for PRGN-2012 for recurrent respiratory papillomatosis patients. Also, Stifel maintained a Buy rating on the stock and raised its price target from $7 to $10.
Portfolio Pulse from Benzinga Newsdesk
Precigen shares are trading higher following positive study data for PRGN-2012 for recurrent respiratory papillomatosis patients. Stifel has maintained a Buy rating on the stock and raised its price target from $7 to $10.
June 03, 2024 | 4:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precigen shares are trading higher due to positive study data for PRGN-2012 and an increased price target from Stifel.
The positive study data for PRGN-2012 is a significant development for Precigen, likely boosting investor confidence. Additionally, Stifel's maintained Buy rating and increased price target from $7 to $10 further supports a positive short-term outlook for the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100